Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun 28;12(7):1715.
doi: 10.3390/cancers12071715.

Efficacy of Panitumumab and Cetuximab in Patients with Colorectal Cancer Previously Treated with Bevacizumab; a Combined Analysis of Individual Patient Data from ASPECCT and WJOG6510G

Hiroya Taniguchi  1   2 , Takeharu Yamanaka  3 , Daisuke Sakai  4 , Kei Muro  2 , Kentaro Yamazaki  5 , Susumu Nakata  6 , Hiroyuki Kimura  7 , Paul Ruff  8 , Tae Won Kim  9 , Marc Peeters  10 , Timothy Price  11
Affiliations

Efficacy of Panitumumab and Cetuximab in Patients with Colorectal Cancer Previously Treated with Bevacizumab; a Combined Analysis of Individual Patient Data from ASPECCT and WJOG6510G

Hiroya Taniguchi et al. Cancers (Basel). .

Abstract

Background: Phase-III ASPECCT and randomised phase-II WJOG6510G trials demonstrated the noninferiority of panitumumab, when compared with cetuximab, for overall survival in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer.

Methods: The subgroup that received bevacizumab either prior to panitumumab or cetuximab monotherapy (ASPECCT) or in combination with irinotecan (WJOG6510G) was included. Multivariate Cox models were created, including the treatment arms as covariates together with patient, disease and treatment characteristics.

Results: We included 185 and 189 patients in the panitumumab and cetuximab arms, respectively. The median overall survival was 12.8 and 10.1 months [p = 0.0031; log-rank test, stratified by trial; hazard ratio (HR), 0.72; 95% confidence interval (CI), 0.58-0.90], and the median progression-free survival was 4.7 and 4.1 months, in the panitumumab and cetuximab arms, respectively (p = 0.0207; HR, 0.79; 95% CI, 0.64-0.97). The treatment regimen was an independent prognostic factor of overall survival (adjusted HR, 0.69; 95% CI, 0.54-0.87; p = 0.0013).

Conclusions: Panitumumab significantly prolonged the overall survival and progression-free survival, when compared with cetuximab in the cohort that previously received bevacizumab in the included studies. Clinical Trial Registration: ASPECCT trial registered with ClinicalTrials.gov (NCT01001377) and WJOG6510G trial registered with UMIN-CTR (UMIN000006643).

Keywords: anti-EGFR therapy; cetuximab; colorectal cancer; panitumumab.

PubMed Disclaimer

Conflict of interest statement

HT reports receiving speakers bureau honoraria from Chugai, Takeda and Merck Serono. TY reports receiving grants from Chugai, Takeda and Merck Serono and speakers bureau honoraria from Chugai and Takeda. KY reports receiving speakers bureau honoraria from Chugai, Takeda and Merck Serono. KM reports grants from Merck Serono, personal fees from Chugai, and personal fees from Takeda. PR reports grants from Amgen. MP reports receiving speakers bureau honoraria from, and is a consultant/advisory board member for, Amgen. TP is a consultant/advisory board member for Amgen, Merck Serono and Takeda. The rest of the authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Study population. The panitumumab or cetuximab monotherapy (ASPECCT)was a phase-III trial of panitumumab versus cetuximab monotherapy. The WJOG6510G was a randomised phase-II trial of panitumumab plus irinotecan, versus cetuximab plus irinotecan. Abbreviations: Bev, bevacizumab; Cmab, cetuximab; Pmab, panitumumab.
Figure 2
Figure 2
Survival analysis. Abbreviations: CI, confidence interval; Cmab, cetuximab; Pmab, panitumumab; OS, overall survival; PFS, progression-free survival.
See this image and copyright information in PMC

References

    1. Karapetis C.S., Khambata-Ford S., Jonker D.J., O’Callaghan C.J., Tu D., Tebbutt N.C., Simes R.J., Chalchal H., Shapiro J.D., Robitaille S.M., et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 2008;359:1757–1765. doi: 10.1056/NEJMoa0804385. - DOI - PubMed
    1. Amado R.G., Wolf M., Peeters M., Cutsem E.V., Siena S., Freeman D.J., Juan T., Sikorski R., Suggs S., Patterson S.D., et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 2008;26:1626–1634. doi: 10.1200/JCO.2007.14.7116. - DOI - PubMed
    1. Price T.J., Peeters M., Kim T.W., Li J., Cascinu S., Ruff P., Suresh A.S., Thomas A., Tjulandin S., Zhang K., et al. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): A randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol. 2014;15:569–579. doi: 10.1016/S1470-2045(14)70118-4. - DOI - PubMed
    1. Price T., Kim T.W., Li J., Cascinu S., Ruff P., Suresh A.S., Thomas A., Tjulandin S., Guan X., Peeter M. Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer. Eur. J. Cancer. 2016;68:51–59. doi: 10.1016/j.ejca.2016.08.010. - DOI - PubMed
    1. Cunningham D., Humblet Y., Siena S., Khayat D., Bleiberg H., Santoro A., Bets D., Mueser M., Harstrick A., Verslype C., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 2004;351:337–345. doi: 10.1056/NEJMoa033025. - DOI - PubMed

Associated data